My understanding is that biotech companies are able to negotiate the best possible partnering deals AFTER they release the final results of their Phase II efficacy trials (assuming they turn out to be as good as they expect).
Given that the Cpn10 trial results were released only a month ago and the oral nadolol trial results are imminent, but not yet released, I would suggest that shareholders be realistic - as deals like these take time to negotiate and then get legal sign-off before they can be announced.
There is every reason to be hopeful that we will be rewarded for our patience.
My understanding is that biotech companies are able to negotiate...
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IVX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
-0.001(20.0%) |
Mkt cap ! $25.69M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $5.78K | 1.445M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 30 | 12797949 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 7472779 | 27 |
View Market Depth
| Last trade - 14.20pm 28/06/2024 (20 minute delay) ? |
| IVX (ASX) Chart |